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Letters to the EditorBiological or relational screening for liver disease?To the Editor:
As a member of the ‘‘discordantist’’ family [1] I agree with Dr. Poy-
nard’s proposal of non invasive methods as a ﬁrst line investigation
forassessmentof liverﬁbrosis [2].However, fromapublichealthand
ﬁnancial point of view, a ‘‘sequentialist’’ attitude in case of liver dis-
ease could probably be a more preferable recommendation.
Another aspect of Dr. Poynard’s proposal to screen general
population for liver ﬁbrosis by using biomarkers is very
questionable:
It seems more satisfactory to screen, at ﬁrst line, the etiological
factors, than for their liver consequences. As pointed in Dr. Poy-
nard’s study [3], in a general population, almost 9 out of 10 cases
of conﬁrmed liver ﬁbrosis can be attributed to metabolic causes
(alcohol and more importantly non alcoholic fatty liver disease).
Instead of considering new biological tests for screening, it is more
important to teach and promote screening, by general practitioners
and other ﬁrst line health professionals, for premature mortality
risk factors: overweight, obesity, and sedentarity related metabolic
syndrome, at risk or excessive alcohol consumption, and tobacco,
without forgetting risk factors for viral hepatitis B and C. Such a
screening should be more efﬁcient from a global individual and
public health point of view: it is possible to have metabolic
syndrome or alcohol excessive intake without conﬁrmed liver
ﬁbrosis but (more frequently!) with other somatic complications
(especially cardiovascular and/or tumoral diseases).
The use of biomarkers without screening for overweight,
obesity, sedentarity, at risk or excessive alcohol consumption,
tobacco, or viral hepatitis B and C risk factors will be nonsense:
if evaluation for conﬁrmed liver ﬁbrosis by biomarkers was posi-
tive, screening for these factors would be a secondary necessity.
However, in case of conﬁrmed liver ﬁbrosis excluded by biomark-
ers, it will be necessary to screen for the same risk factors. So
what is the interest to test the general population by biomarkers,
instead of only screening for suspected liver ﬁbrosis in patients
with risk factors?
At this state of the discussion, a frequent comment is: ‘‘you
could be right but after the recognition of risk factors, what do
you propose?’’ suggesting a negative answer. But the same
answer is also possible (except in case of cirrhosis) after bio-
markers screening for metabolic liver disease! And in fact this
comment is wrong: a lot of Evidence Based Medicine (EBM)
behavioral and cognitive data has been published, showingJournal of Hepatologysigniﬁcant and durable results in weight loss and physical
activity in patients with overweight, obesity, and diabetes.
These results have been conﬁrmed recently for patients with
non alcoholic steatohepatitis [4]. It is not the place to develop
more extensively this aspect, but just one example: a very
recent paper showed a strong association between practitioners
saying clearly to the patient the diagnosis of obesity, its impor-
tance for health, and the obtention of signiﬁcant and durable
weight loss [5]. We have to look carefully not only for EBM
data about biological and morphological tests, drug, or surgical
treatment but also for behavioral and cognitive EBM data. Sci-
entiﬁc rigour should not accept fragmentation and only par-
tially taking into account available data.
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To the Editor:
We read with interest the paper of Kurosaki and colleagues [1]
and applaud their use of data mining to develop a decision tree
to predict HCV treatment outcomes. We agree with them that
prediction of treatment outcome is very important in the process
of physician and patient making a decision to commence treat-2011 vol. 55 j 1162–1167
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ment for HCV infection, especially genotype 1. This prevents
futile therapy in patients with little chance of cure, and the deci-
sion tree presentation also offers the opportunity for patients to
be actively involved in setting the level of futility. Thus, they have
developed a clinically useful negative predictive tool. However,
with the advent of protease inhibitors and the greatly increased
cost of these therapies, identifying the patients who would be
cured with standard of care, a positive predictive tool is now even
more important, if we are to reduce the implementation costs of
these new drugs to maximise beneﬁt for all patients. Clearly a
pre-treatment prediction tool would be useful, but not essential,
if the decision to treat has been made and the tool is to be used to
individualise therapy. Some of the new therapies propose a 4-
week run in therapy with interferon and ribavirin before starting
a protease inhibitor. There being arguments for using this regi-
men to reduce risk of viral resistance in all therapies. Thus a tool
incorporating a rapid virological response (RVR) at 4 weeks [2]
would still be useful if it had a signiﬁcant positive predictive
value. We still have a very incomplete understanding of the fac-52%
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Journal of Hepatology 201tors that determine interferon sensitivity. Polymorphisms around
the IL28 gene are clearly important but do not account for the
whole variance in interferon response seen in patients, in terms
of SVR. The analysis of this polymorphism has not been estab-
lished as a routine test outside a research setting, so its availabil-
ity and reliability is limited at present. An early response time
point, such as a 4 week RVR, dynamically tests a given patient
and virus’ interferon sensitivity, and provides a global test of
response factors including the inﬂuence of IL28B polymorphisms
and the ISDR mutations in the HCV virus. The ISDR mutations in
HCV are associated with host hepatic steatosis and lipid dysreg-
ulation, this has been correlated with elevation of GGT. We,
therefore, used the decision tree developed by Kurosaki and col-
leagues and substituted RVR for IL28B genotype and GGT for ISDR,
to see if these commonly available measures changed the func-
tion of the tool as a positive predictor of SVR in therapy with
interferon and ribavirin. We applied the decision tree tool to
our consecutively treated cohort of 114 HCV genotype 1 patients
for whom we had RVR data, as demonstrated in Fig. 1. The cohort16%
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is predominantly Caucasian, male (75%), younger (mean age 43),
and has a higher proportion of current and former drug users
(68%), than the Japanese cohort. We also had a lower prevalence
of cirrhosis (11%). These differences meant that some parts of the
decision tree were under populated. However, the tree was able
to identify a subgroup of patients who achieved a RVR, with nor-
mal platelets and a low viral load, representing 17.5% of the
cohort who had a 90% chance of achieving a SVR with standard
of care combination therapy. This level of SVR means it is much
more cost-effective to treat such patients with standard peginter-
feron and ribavirin than to add a protease inhibitor as ﬁrst line
therapy. Equally there is currently no evidence that the protease
inhibitors will improve the outcome in this patient group. We
congratulate Kurosaki and colleagues on an easy to use tool that
helps patients and physicians make decisions on starting therapy
and that with minor modiﬁcations may make the impact of the
introduction of protease inhibitors much more cost effective.
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pegylated-interferon plus ribavarin for chronic hepatitis C using RVR’’Decision model incorporating IL28B genotype and ISDR could
identify patients with high probability of SVR among patients
who failed to achieve RVR
To the Editor:
We appreciate the interest of Dr. Wahed in our article recently
published in the Journal of Hepatology [1]. We were impressed
of their validation of our prediction model by substituting rapid
virological response (RVR) for IL28B genotype (modiﬁed model)
[2]. Wahed et al. showed that among patients with RVR, those
with high platelet counts (P140  109/L), and low HCV RNA
(<600,000 IU/ml)) had 90% chance of sustained virological
response (SVR). Their results conﬁrmed our ﬁnding that platelet
count and pretreatment HCV RNA level are predictors of SVR,
independently of early virological dynamics and showed that
combination of these factors improved the prediction accuracy.
However, according to their data, a modiﬁed model could not
identify patients who have high chance of SVR among those
who failed to achieve RVR.
In a study by Thompson et al. [3], RVR was correlated with
the IL28B genotype and was a strong predictor of SVR regard-
less of IL28B genotype. On the other hand, the major IL28B
genotype (CC at rs12979860) was associated with a higher rate
of SVR (among Caucasians, 66% (IL28B major genotype) vs. 31%
(IL28B minor hetero-genotype) and 24% (IL28B minor geno-
type)) among patients who failed to achieve RVR. There were
similar ﬁndings in our cohort, where patients with RVR had ahigh rate of SVR independent of IL28B genotype (97% for
IL28B major type vs. 100% for IL28B minor type) but among
non-RVR patients, the IL28B major genotype was associated
with signiﬁcantly higher rate of SVR (45% for IL28B major geno-
type vs. 12% for IL28B minor genotype). Collectively, IL28B
genotype has a signiﬁcant predictive power even after virolog-
ical response at week 4 of therapy was determined. This means
that RVR is associated with IL28B genotype but RVR could not
entirely replace IL28B genotype for the accurate prediction of
SVR. In order to assess if our model still has the power to pre-
dict SVR after virological response at week 4 of therapy was
determined, we modiﬁed our predictive model by adding RVR
as a ﬁrst splitting variable and applied the data of our cohort.
As a result, among patients who failed to achieve RVR in our
cohort, patients with IL28B major genotype who had (1) high
platelet counts (P140  109/L), and low HCV RNA
(<600,000 IU/ml) had 87% chance of SVR, (2) high platelet
counts (P140  109/L), and high HCV RNA (P600,000 IU/ml)
had 60% chance of SVR, and (3) low platelet counts
(<140  109/L), and more than 2 mutations in interferon sensi-
tivity determining region (ISDR) [4] had 69% chance of SVR
(Fig. 1). Patients who fall into these three groups constitute
39% of non-RVR patients. Thus, our predictive model could
determine patients with high probability of SVR even after
virological response at week 4 of therapy was determined.
We fully agree with Dr. Wahed that it is important to iden-
tify the patients who would be cured with current standard ofvol. 55 j 1162–1167
